Incorporation of liposome-encapsulated amphotericin in artificial/prosthetic cardiac valves for therapy and prevention of fungal endocarditis.
Fungal endocarditis is a highly fatal condition. Fungal prosthetic valve endocarditis is an uncommon but serious infection. Patients require surgery and long-term antifungal therapy. However, recurrence is quite common and eradication of infection is difficult. Liposomal amphotericin is considered to be better than the conventional preparation. It is hypothesized that incorporation of liposome-encapsulated amphotericin inside artificial/prosthetic cardiac valves would result in better tissue concentration of the drug at site of infection and probable prevention of recurrence. The cost of making the same might be considerable but would likely be cost-effective in the long run due to lowered mortality and prevention of recurrence.
Ratna S
W V
WV
D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D004696:Endocarditis / Q000188:drug therapy* / Q000517:prevention & control*; D006350:Heart Valve Prosthesis; D006801:Humans; D008081:Liposomes; D008954:Models, Biological; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control*; D012008:Recurrence
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B